SSG
LFCR icon

Summit Securities Group’s Lifecore Biomedical LFCR Stock Holding History

Summit Securities Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-582
Closed -$4.28K – 1143
2025
Q3 		$4.28K Buy
+582
New +$4.4K ﹤0.01% 931
2025
Q2 		– Sell
-3,690
Closed -$26K – 1266
2025
Q1 		$26K Buy
+3,690
New +$22.9K ﹤0.01% 429

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return

Summit Securities Group's LFCR Position: Q4 2025 in Review

Summit Securities Group sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 582 shares — an estimated $4.28K sold.

Summit Securities Group first reported a position in LFCR in Q1 2025 and held it in 2 quarters. The position peaked at $26K in Q1 2025. 104 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

  • Summit Securities Group reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
  • Summit Securities Group sold 582 Lifecore Biomedical shares in Q4 2025, an estimated $4.28K.
  • Summit Securities Group first reported a position in Lifecore Biomedical in Q1 2025 and held it in 2 quarters.
  • Summit Securities Group's Lifecore Biomedical position peaked at $26K in Q1 2025.
  • 104 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Summit Securities Group's 13F filing for Q4 2025, filed 17 Feb 2026.